| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Haemonetics Corporation$76.19
+1.19 (+1.59%)
D 25Pipeline Score MedTech · Commercial
Market Cap
2.98 B
EPS
2.04
P/E Ratio
32.23 $
Value Trade
48.84 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.33 B
R&D Expenses
59.77 M
Operating CF
293.22 M
Total Assets
2.40 B
Total Liabilities
2.40 B
Equity
796.32 M
D/E Ratio
12,345
14.35 %
Week
8.39 %
1 Month
7.54 %
3 Month
-13.52 %
6 Month
14.96 %
5 Year
1,002.99 %
All Time
Cash Data
Cash Position
264.64 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 20, 2026
Overview
Volume
456.26 K
52 Week Range
47.32 - 87.32
% held by Insiders
1.84 %
% held by Institutions
105.95 %
Enterprise Value
4.01 B
Total Shares
46.46 M
Short %
6.36 %
Float Shares
45.81 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D25
Pipeline Score $86M
Pipeline ValueValuation Signal
2
Drugs Scored0.1x
rNPV / MCap Top 25%
Small Cap (rank 684 of 911)
Percentile RankHaemonetics Corporation faces pipeline headwinds (25/100), with $132M risk-adjusted pipeline value, led by Fibrinogen in Postpartum Haemorrhage (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fibrinogen Small molecule | Postpartum Haemorrhage | Phase 2 | NCT01359878 | 14% | $97M | COMPLETED | 249 | - | - | Jul 1, 2013 | - | Sep 20, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HAE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HAE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HAEInvestor Contacts Media Contact Olga Guyette, Vice President - Investor Relations Treasury (781) 356-9763 olga.guyette haemonetics.com Josh Gitelson, Sr. Director - Global Communications (781) 356-9776 josh.gitelson haem
Haemonetics Corporation has announced a new financial reporting segment structure, transitioning from three segments to two. The previous Plasma and Blood Center segments will now be consolidated into the Apheresis segment, while the Hospital segment will be renamed MedSurg. This reorganization is designed to better reflect the company's operational focus and to align disclosures with the new structure. Haemonetics plans to begin reporting results under this new structure with the first quarter of fiscal year 2027, commencing on March 29, 2026.
Read more →HAEHaemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Haemonetics Corporation will have its President and CEO, Chris Simon, participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The event will be available for public viewing through a live webcast, with a replay accessible for 90 days afterward. The company focuses on enhancing healthcare through innovative medical technologies.
Read more →HAEInvestor Contacts Media Contact Olga Guyette, Vice President-Investor Relations Treasury Josh Gitelson, Sr. Director- Global Communications (781) 356-9763 (781) 356-9776 olga.guyette haemonetics.com josh.gitelson haemone
Haemonetics Corporation reported its fourth quarter and fiscal 2026 financial results, revealing a 4.8% increase in revenue to $346 million. Despite this growth in revenue, the company faced operating losses of $23 million and a decrease in gross margin. The report showed strong performance in its Plasma and Blood Management Technologies, while the acquisition of Vivasure Medical Limited did not impact organic revenue growth. The company provided guidance for fiscal 2027, expecting a reported revenue growth of 4-7%.
Read more →HAENew Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
Haemonetics Corporation announced a new study highlighting the VASCADE MVP® XL's efficacy and safety in large-bore venous access closure procedures. The study demonstrated superior performance compared to the VASCADE MVP® system, achieving 0% bleeding complications. The FDA has approved expanded labeling for the VASCADE MVP XL, allowing its use with larger procedural sheaths, enhancing its role in electrophysiology.
Read more →HAEHaemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
Haemonetics Corporation has received FDA approval to expand the labeling of its VASCADE MVP XL venous vascular closure system for use with larger procedural sheaths. This approval is based on the successful AMBULATE EXPAND trial, which demonstrated no complications in patients. The expansion allows for broader application in advanced vascular closure procedures, particularly in pulsed field ablation and left atrial appendage closure.
Read more →HAEHaemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
Haemonetics Corporation has received FDA 510(k) clearance for its NexSys PCS Plasma Collection System featuring Persona PLUS technology. This next-generation system aims to enhance plasma collection efficiency, showing a mid-single digit percent increase in plasma volume per donation based on clinical trial results. The clearance supports the company's commitment to innovation in plasma-derived therapies.
Read more →HAEHaemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient...
Haemonetics Corporation has received FDA 510(k) clearance for its NexSys PCS Plasma Collection System featuring Persona PLUS technology. This next-generation system aims to improve plasma collection efficiency, yielding higher plasma volumes per donation. The clearance is backed by a pivotal trial involving over 30,000 donations, showcasing its safety and effectiveness. This innovation addresses the growing demand for plasma-derived therapies.
Read more →HAEHaemonetics to Present at Raymond James 47th Annual Institutional Investors Conference Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond...
Haemonetics Corporation announced that CEO Chris Simon will participate in a fireside chat at the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026. The event will be accessible via a live webcast, with a replay available for 90 days afterward. This engagement aims to enhance investor relations and showcase the company's medical technology innovations.
Read more →HAEHaemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Haemonetics Corporation has made its financial results for the third quarter of fiscal 2026 available on its Investor Relations website. The results cover the period ending December 27, 2025. A conference call and webcast are scheduled for February 5, 2026, at 8:00 a.m. ET to discuss these results.
Read more →HAEInvestor Contacts Media Contact Olga Guyette, Vice President-Investor Relations Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette haemonetics.com josh.gitelson haemonetics.com
Haemonetics Corporation reported its financial results for the third quarter of fiscal 2026, revealing a total revenue of $339 million, which is a 2.7% decline compared to the prior year. Despite this decrease, the company reported growth in adjusted earnings per diluted share and cash flow from operations. The company's CEO expressed confidence in their core businesses, citing blood management technologies and plasma as driving strong performance. They have also raised their fiscal 2026 guidance for adjusted earnings per share and free cash flow.
Read more →HAEHaemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are...
Haemonetics Corporation has announced the availability of its financial results for the third quarter of fiscal year 2026, which concluded on December 27, 2025. The results can be accessed on the Company's Investor Relations website. A conference call and webcast will be held on February 5, 2026, to discuss these results with investors and analysts.
Read more →HAEHaemonetics Acquires Vivasure Medical Limited
Haemonetics Corporation has acquired Vivasure Medical Limited, a company specializing in percutaneous vessel closure technology. The acquisition includes an upfront payment of €100 million and potential additional payments based on sales growth. Vivasure's PerQseal Elite system offers a sutureless solution for large-bore arteriotomies and venotomies, with promising clinical results. This move aims to strengthen Haemonetics' position in the structural heart and endovascular procedure markets.
Read more →HAEInvestor Contacts Olga Guyette, VP-Investor Relations Treasury (781) 356-9763 olga.guyette haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk haemonetics.com Media Contact Josh Gitelson, S
Haemonetics Corporation has announced the acquisition of Vivasure Medical Limited, a company focused on innovative vessel closure technologies, for $100 million. The acquisition aims to enhance Haemonetics' product portfolio with Vivasure's PerQseal Elite system, known for its bioabsorbable patch technology, which shows promising clinical results. This acquisition supports Haemonetics' expansion in structural heart and endovascular markets, all financed by available cash. The strong safety and performance data of the PerQseal Elite positions Haemonetics for increased leadership in advanced closure technologies.
Read more →HAEHaemonetics Acquires Vivasure Medical Limited Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient...
Haemonetics Corporation has acquired Vivasure Medical Limited, a company specializing in advanced vessel closure technology. The acquisition includes an upfront payment and potential additional payments based on sales growth. Vivasure's PerQseal Elite system has demonstrated strong clinical results, positioning Haemonetics to enhance its offerings in the large-bore closure market.
Read more →HAEHaemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on...
Haemonetics Corporation has announced the date for its third quarter fiscal year 2026 financial results, which will be published on February 5, 2026, at 6:00 am ET. Following the release, the company will host a conference call at 8:00 am ET to discuss the results and answer questions. Participants can access the call via teleconference or a live webcast.
Read more →HAEHaemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Haemonetics Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference, with CEO Chris Simon scheduled to speak on January 13, 2026. The presentation will be available via a live audio webcast, and a replay will be accessible for 30 days afterward. This event highlights Haemonetics' role in advancing healthcare technology.
Read more →HAEHaemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference...
Haemonetics Corporation announced that its President and CEO, Chris Simon, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be accessible via a live audio webcast, with a replay available for 30 days. This event underscores Haemonetics' commitment to advancing healthcare technology.
Read more →HAE▲ +32.3%on this news
Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are...
Haemonetics Corporation has released its financial results for the second quarter of fiscal year 2026, which ended on September 27, 2025. The results are available on their Investor Relations website. A conference call and webcast are scheduled for November 6, 2025, to discuss the results with investors and analysts.
Read more →HAEHaemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on...
Haemonetics Corporation has announced the date for its second quarter fiscal year 2026 financial results, which will be published on November 6, 2025. The company will also hold a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results. A live webcast will be available for those unable to attend the call.
Read more →HAE▼ -26.6%on this news
Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available ...
Haemonetics Corporation announced the availability of its financial results for the first quarter of fiscal year 2026, which ended on June 28, 2025. The company will hold a conference call and webcast on August 7, 2025, at 8:00 a.m. ET to discuss these results. Interested participants can access the call through a provided teleconference link.
Read more →HAEHaemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on...
Haemonetics Corporation plans to release its first quarter fiscal year 2026 financial results on August 7, 2025. The announcement includes a conference call for investors and analysts to discuss the results. Participants are encouraged to join early, and a replay will be available for a year after the event.
Read more →HAEHaemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman...
Haemonetics Corporation announced that its CEO, Chris Simon, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025. The event will be accessible via a live webcast, with a replay available for 90 days afterward. This engagement reflects Haemonetics' commitment to investor relations.
Read more →HAE▲ +5.9%on this news
Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 olga.guyette haemonetics.com josh.gitelson haemonet
Haemonetics Corporation reported its financial results for the fourth quarter and fiscal 2025. While the revenue decreased by 3.7% in Q4 compared to the previous year, the company experienced solid earnings growth, with adjusted earnings increasing by 37.8%. The company announced a new share repurchase program of up to $500 million to support shareholder value. Guidance for fiscal 2026 indicates anticipated revenue challenges in certain segments, particularly Plasma and Blood Center, while Hospital revenue is projected to grow.
Read more →HAE▲ +5.9%on this news
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are...
Haemonetics Corporation has released its financial results for the fourth quarter and fiscal year 2025, which ended on March 29, 2025. The company will hold a conference call and webcast on May 8, 2025, at 8:00 a.m. ET to discuss these results. Additional earnings information and revenue growth guidance are also available on their Investor Relations website.
Read more →HAEHaemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET ...
Haemonetics Corporation has announced the publication date for its fourth quarter and fiscal year 2025 financial results, set for May 8, 2025. The company will hold a conference call at 8:00 am ET on the same day to discuss the results with investors and analysts. A live webcast will also be available for those interested.
Read more →HAEInvestor Contacts Olga Guyette, Vice President-Investor Relations Treasury (781) 356-9763 olga.guyette haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk haemonetics.com Media Contact Josh
Haemonetics Corporation has announced key updates to its executive leadership team, welcoming Frank Chan as the new Executive Vice President and Chief Operating Officer, and promoting Roy Galvin to Executive Vice President and Chief Commercial Officer. Chan, who has over 25 years of experience in healthcare technology, will oversee research, development, and global operations. Galvin will expand his responsibilities to include the Global Hospital business, indicating a strategic focus on growth and innovation. These leadership changes are part of Haemonetics' plan to drive the next phase of its business expansion.
Read more →HAEHaemonetics Announces Executive Leadership Updates Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has announced key updates to its executive leadership team, appointing Frank Chan as Chief Operating Officer and promoting Roy Galvin to Chief Commercial Officer. Chan, with over 25 years of experience, will oversee R&D and operational excellence, while Galvin will direct commercialization initiatives for the company's Global Hospital business. These changes aim to support Haemonetics' growth strategy.
Read more →HAEHaemonetics to Present at Raymond James 46th Annual Institutional Investors Conference Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond...
Haemonetics Corporation announced that its President and CEO, Chris Simon, will participate in a fireside chat at the Raymond James 46th Annual Institutional Investors Conference on March 4, 2025. The event will be accessible to the public via a live webcast, with a replay available for 90 days afterward. This participation highlights Haemonetics' commitment to transparency and investor engagement.
Read more →HAE▼ -11.6%on this news
Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are...
Haemonetics Corporation has made its financial results for the third quarter of fiscal year 2025 available on its Investor Relations website. The results, covering the period ending December 28, 2024, will be discussed in a conference call scheduled for February 6, 2025. Participants can access the call via a provided teleconference link.
Read more →HAEInvestor Contacts Media Contact Olga Guyette, Vice President-Investor Relations Treasury (781) 356-9763 olga.guyette haemonetics.com Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 josh.gitelson haemonet
Haemonetics Corporation has completed the sale of its whole blood assets to GVS, S.p.A for up to $67.8 million. This transaction includes an upfront payment of $45.3 million and contingent earn-outs over four years. The proceeds will be utilized for corporate purposes and growth initiatives. Despite this strategic move, Haemonetics may face risks regarding the realization of expected benefits and changes in market demand. The company remains committed to its Blood Center business, continuing to provide apheresis solutions.
Read more →HAEHaemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has finalized the sale of its whole blood assets to GVS, S.p.A for up to $67.8 million. This includes an upfront payment and contingent earn-outs. The proceeds will support Haemonetics' growth initiatives. The company will continue to operate its Blood Center business, focusing on apheresis solutions.
Read more →HAEHaemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on...
Haemonetics Corporation has announced the date for its third quarter fiscal year 2025 financial results, which will be published on February 6, 2025. The company will host a conference call at 8:00 am ET on the same day to discuss the results with investors and analysts. A live webcast will also be available, along with a replay for one year.
Read more →HAEHaemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference...
Haemonetics Corporation announced that its President and CEO, Chris Simon, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2025. The presentation will be available via live audio webcast, and a replay will be accessible for 30 days afterward. This event highlights Haemonetics' commitment to innovative healthcare solutions.
Read more →HAEHaemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has announced the sale of its whole blood assets to GVS, S.p.A for up to $67.1 million. The deal includes an upfront payment and contingent earn-outs, with the transaction expected to close in early 2025. Haemonetics will continue to operate its Blood Center business, focusing on apheresis solutions.
Read more →HAE▲ +10.7%on this news
Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are...
Haemonetics Corporation has made its financial results for the second quarter of fiscal year 2025 available online. The results cover the period ending September 28, 2024. A conference call and webcast are scheduled for November 7, 2024, at 8:00 a.m. ET to discuss these results with investors and analysts.
Read more →HAEHaemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on...
Haemonetics Corporation has announced the publication date for its second quarter fiscal year 2025 financial results, which will be released on November 7, 2024. A conference call for investors and analysts will follow at 8:00 am ET on the same day. Participants can access the call via teleconference or through a live webcast on the company's investor relations website.
Read more →HAEHaemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, ...
Haemonetics Corporation has announced the full market release of its VASCADE MVP XL vascular closure system, which features advanced technology for improved patient outcomes. The system is designed for use in various procedures requiring larger sheaths and has received positive feedback from physicians during its limited release. The company aims to expand its indications through ongoing clinical trials.
Read more →HAE▼ -10.8%on this news
Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available ...
Haemonetics Corporation has made its financial results for the first quarter of fiscal year 2025 available on its Investor Relations website. The results pertain to the period ending June 29, 2024. A conference call and webcast to discuss these results will take place on August 8, 2024, at 8:00 a.m. ET.
Read more →HAEHaemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has received CE Mark certification for its SavvyWire Pre-Shaped Pressure Guidewire, the first sensor-guided solution for Transcatheter Aortic Valve Implantation (TAVI). The guidewire aims to improve procedural efficiency and patient outcomes. Initial commercial procedures have been successfully conducted in France and the Netherlands, marking a significant step in the company's international expansion.
Read more →HAEHaemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2025 financial results at 6:00 am ET on...
Haemonetics Corporation has announced the publication date for its first quarter fiscal year 2025 financial results, which will be released on August 8, 2024. A conference call for investors and analysts is scheduled for the same day to discuss the results. Participants are encouraged to join early for the call, which will also be available via webcast.
Read more →HAEHaemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, ...
Haemonetics Corporation has launched a limited market release of its new VASCADE MVP XL vascular closure device, enhancing its existing VASCADE portfolio. This device features innovative technology aimed at promoting rapid hemostasis and is designed for procedures requiring larger sheaths. The system has received pre-market approval from the FDA and is expected to address the growing demand for catheter-based ablation technologies.
Read more →HAEHaemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50%...
Haemonetics Corporation has announced the pricing of a $600 million private placement of 2.50% Convertible Senior Notes due 2029, increasing the offering size from $525 million. The offering is set to close on May 28, 2024, and the proceeds will be used for various financial strategies, including repurchasing existing notes and improving working capital. The notes offer conversion options for investors, although they carry risks related to market conditions and potential dilution.
Read more →HAEInvestor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 olga.guyette@haemonetics.com david.trenk@haemonetics.com Media Contact: Jo
Haemonetics Corporation announced the successful pricing of an upsized offering of $600 million in 2.50% Convertible Senior Notes due 2029, initially set at $525 million. The offering is set to close on May 28, 2024, and aims to provide Haemonetics with approximately $584.8 million in net proceeds. These funds will be allocated towards refinancing existing debt and general corporate purposes, improving their financial position. The notes feature specific conversion rights, redemption options, and a capped call transaction to offset potential dilution of shares.
Read more →HAEHaemonetics Announces Proposed Convertible Senior Notes Offering Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000...
Haemonetics Corporation announced its intention to offer $525 million in Convertible Senior Notes due 2029. The notes will be available to qualified institutional buyers and will accrue interest payable semi-annually. Proceeds from the offering will be used for working capital and other corporate purposes, including capped call transactions to manage potential dilution.
Read more →HAEHaemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are...
Haemonetics Corporation has made its financial results for the fourth quarter and fiscal year 2024 available on its Investor Relations website. The company will conduct a conference call and webcast on May 9, 2024, to discuss these results with investors and analysts. Additional resources, including historical revenue information, are also accessible online.
Read more →HAEInvestor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette haemonetics.com josh.gitelson haemonetics.com David
Haemonetics Corporation (NYSE: HAE) reported strong financial results for the fourth quarter and fiscal year 2024, with annual revenue reaching $1.309 billion, a 12% increase. The company reported an adjusted earnings per diluted share of $0.90, up 16.9% compared to the previous year, and highlighted positive growth in various business units. However, the gross margin saw a slight decrease due to foreign exchange impacts and increased operating expenses. Looking forward, Haemonetics has issued guidance for fiscal 2025, projecting revenue growth despite expected challenges in certain segments.
Read more →HAEHaemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET ...
Haemonetics Corporation has announced the date for its fourth quarter and fiscal year 2024 financial results, which will be published on May 9, 2024. A conference call for investors and analysts is scheduled for the same day at 8:00 am ET. Participants can access the call via teleconference or through a live webcast on the company's investor relations website.
Read more →HAEHaemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has received FDA 510(k) clearance for its TEG 6s Global Hemostasis-HN assay cartridge. This new cartridge is designed for use in adult cardiovascular surgeries and liver transplantation, improving hemostasis management for patients on heparin. The clearance was supported by clinical data from trials involving over 500 patients, demonstrating its safety and effectiveness.
Read more →HAEHaemonetics Corporation Completes Acquisition of Attune Medical Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has finalized its acquisition of Attune Medical, known for its ensoETM esophageal cooling device. The deal involves an upfront payment of $160 million, with additional contingent payments tied to sales growth. Haemonetics anticipates a revenue contribution of $30 to $35 million from Attune in fiscal year 2025, while managing increased debt levels due to the acquisition financing.
Read more →HAEInvestor Contacts Olga Guyette, Sr. Director-Investor Relations Treasury (781) 356-9763 olga.guyette haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk haemonetics.com Media Contact Josh G
Haemonetics Corporation has completed the acquisition of Attune Medical, known for its ensoETM esophageal cooling device, at a cost of $160 million with additional contingent payments based on sales growth. This device is the only FDA-cleared temperature regulation option for esophageal protection during cardiac procedures. Haemonetics expects the acquisition to bolster its revenue and earnings in fiscal 2025, although the company will incur debt to finance the deal, raising concerns about increased indebtedness. The company has provided forward-looking statements regarding the anticipated financial impacts and risks involved with the acquisition.
Read more →HAEHaemonetics Announces Definitive Agreement to Acquire Attune Medical Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical products and solutions to drive...
Haemonetics Corporation has announced a definitive agreement to acquire Attune Medical for $160 million, plus contingent payments based on future sales growth. The acquisition aims to enhance Haemonetics' presence in the electrophysiology market with Attune's ensoETM device, which is FDA-cleared for esophageal protection during cardiac ablation procedures. The deal is expected to close in the first quarter of fiscal year 2025.
Read more →HAEHaemonetics to Present at Raymond James 45th Annual Institutional Investors Conference Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond...
Haemonetics Corporation announced that its President and CEO, Chris Simon, will participate in a fireside chat at the Raymond James 45th Annual Institutional Investors Conference on March 5, 2024. The event will be accessible via a live webcast, with a replay available for 90 days afterward. This engagement highlights Haemonetics' commitment to investor relations.
Read more →HAEHaemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at Citi's 2024...
Haemonetics Corporation announced that its President and CEO, Chris Simon, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day on February 29, 2024. The event will be accessible via a live webcast, with a replay available afterward. This engagement highlights Haemonetics' commitment to investor relations and transparency.
Read more →HAEHaemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2024, which ended December 30, 2023, are...
Haemonetics Corporation has made its financial results for the third quarter of fiscal year 2024 available on its Investor Relations website. The results pertain to the period ending December 30, 2023. A conference call and webcast are scheduled for February 8, 2024, at 8:00 a.m. ET to discuss these results.
Read more →HAEHaemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2024 financial results at 6:00 am ET on...
Haemonetics Corporation has announced the date for its third quarter fiscal year 2024 financial results, which will be published on February 8, 2024. A conference call for investors and analysts is scheduled for the same day to discuss the results. Participants are encouraged to join early for the call, which will also be available via a live webcast.
Read more →HAEHaemonetics Corporation Completes Acquisition of OpSens Inc. Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has completed the acquisition of OpSens Inc. for CAD $2.90 per share, valuing the deal at approximately USD $255 million. This acquisition is expected to enhance Haemonetics' Hospital portfolio with innovative cardiology products and is projected to contribute significantly to revenue in fiscal year 2025. The company has also raised its revenue growth guidance for fiscal year 2024.
Read more →HAEHaemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference...
Haemonetics Corporation announced that its President and CEO, Chris Simon, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will be available for public access through a live audio webcast. A replay will be accessible for 30 days following the event.
Read more →HAEHaemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2024, which ended September 30, 2023, are...
Haemonetics Corporation has released its financial results for the second quarter of fiscal year 2024, ending September 30, 2023. The results are available on their Investor Relations website, and the company will host a conference call on November 2, 2023, to discuss these results with investors and analysts. A replay of the call will be accessible for one year following the event.
Read more →HAEHaemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc. Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has announced a definitive agreement to acquire OpSens, Inc. for CAD $2.90 per share, totaling approximately USD $253 million. This acquisition aims to enhance Haemonetics' offerings in interventional cardiology, leveraging OpSens' innovative fiber optic sensor technology. The transaction is expected to close by January 2024, pending necessary approvals.
Read more →HAEHaemonetics Sets Date for Publishing Second Quarter Fiscal Year 2024 Results: November 2, 2023 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on...
Haemonetics Corporation plans to release its second quarter fiscal year 2024 financial results on November 2, 2023, at 6:00 am ET. Following the announcement, a conference call will be held at 8:00 am ET for investors and analysts to discuss the results. Participants can access the call via teleconference or through a live webcast on the company's investor relations website.
Read more →HAEHaemonetics Announces European Expansion for VASCADE® Vascular Closure System Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has announced the first treatment of its VASCADE MVP Venous Vascular Closure system in Germany, marking its European debut. The VASCADE system is designed for efficient femoral arterial and venous closure, enhancing patient care in interventional cardiology. Following Germany, the system is set for release in Italy and Japan, indicating Haemonetics' commitment to global market expansion.
Read more →HAEHaemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal 2024, which ended July 1, 2023, are available on...
Haemonetics Corporation has made its financial results for the first quarter of fiscal year 2024 available on its Investor Relations website. The results pertain to the quarter ending July 1, 2023. A conference call and webcast are scheduled for August 8, 2023, at 8:00 a.m. ET to discuss these results with investors and analysts.
Read more →HAEDiane M. Bryant Joins Haemonetics' Board of Directors Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient...
Haemonetics Corporation has elected Diane M. Bryant to its Board of Directors. Bryant, with over 30 years of experience in technology and healthcare, previously served as CEO of NovaSignal Corp. and COO of Google Cloud. Her expertise is anticipated to support Haemonetics in achieving long-term growth objectives.
Read more →HAEHaemonetics Sets Date for Publishing First Quarter Fiscal Year 2024 Results: August 8, 2023 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2024 financial results at 6:00 am ET on...
Haemonetics Corporation has announced the publication date for its first quarter fiscal year 2024 financial results, scheduled for August 8, 2023. The company will hold a conference call at 8:00 am ET on the same day to discuss the results with investors and analysts. A live webcast will also be available, ensuring accessibility for stakeholders.
Read more →HAEInvestor Contact Media Contact Olga Guyette, Sr. Director-Investor Relations Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette haemonetics.com josh.gitelson haemonetics.com Haemon
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Sr. Director-Investor Relations Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette haemonetics.com josh.gitelson haemonetics.com Haemonetics Reports Second Quarter and Fir
Read more →HAEInvestor Contact Olga Guyette, Director-Investor Relations (781) 356-9763 olga.guyette haemonetics.com Media Contact Josh Gitelson, Director-Global Communications (781) 356-9776 josh.gitelson haemonetics.com Haemonetics
Haemonetics Appoints James D'Arecca Chief Financial Officer Boston, MA, March 21, 2022 -- Haemonetics Corporation (NYSE HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022. He will repor
Read more →HAE▲ +16.2%on this news
Investor Contact Media Contact Olga Guyette, Director-Investor Relations Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette haemonetics.com josh.gitelson haemonetics.com Haemonetics Reports
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette haemonetics.com josh.gitelson haemonetics.com Haemonetics Reports Third Quarter and Year-to-Date Fisc
Read more →HAEInvestor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports F
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports Fourth Quarter and Fiscal 2021 Result
Read more →HAEInvestor Contact Olga Guyette, Director-Investor Relations (781) 356-9763 olga.guyette haemonetics.com Media Contact Carla Burigatto, Vice President-Communications (781) 348-7263 carla.burigatto haemonetics.com
HAEMONETICS PROVIDES UPDATE ON U.S. PLASMA BUSINESS BOSTON, MA, April 19, 2021 - Haemonetics Corporation (NYSE HAE) ("Haemonetics" or the "Company"), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today an
Read more →HAEHaemonetics Prices $435.0 Million Convertible Senior Notes Offering BOSTON
Haemonetics Prices $435.0 Million Convertible Senior Notes Offering BOSTON, March 2, 2021-Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2026 (the
Read more →HAEHaemonetics Announces Proposed Convertible Senior Notes Offering BOSTON
Haemonetics Announces Proposed Convertible Senior Notes Offering BOSTON, March 1, 2021-Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $425,000,000 aggregate principal amount of Convertible Se
Read more →HAEInvestor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports T
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports Third Quarter and Year-to-Date Fiscal
Read more →HAEInvestor Contact Olga Guyette, Director-Investor Relations (781) 356-9763 olga.guyette haemonetics.com Media Contact Carla Burigatto, Vice President-Communications (781) 348-7263 carla.burigatto haemonetics.com HAEMONETI
HAEMONETICS TO ACQUIRE CARDIVA MEDICAL, INC. TO EXPAND HOSPITAL PORTFOLIO Enhances penetration into the large and growing interventional cardiology and electrophysiology markets Offers products with demonstrated and differentiated clinical benefits Expected to be accretive to
Read more →HAEInvestor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports S
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports Second Quarter and 1st Half Fiscal 20
Read more →HAEInvestor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports 4
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports 4th Quarter and Fiscal 2020 Results
Read more →HAEInvestor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports 3
Exhibit 99.1 Investor Contact Media Contact Olga Guyette, Director-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports 3rd Quarter and Year-to-Date Fiscal
Read more →HAEEarnings Release FY20 Q2 Investor Contact Media Contact Olga Guyette, Sr. Mgr.-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.
Exhibit 99.1 Earnings Release FY20 Q2 Investor Contact Media Contact Olga Guyette, Sr. Mgr.-Investor Relations Carla Burigatto, VP-Communications (781) 356-9763 (781) 348-7263 olga.guyette haemonetics.com carla.burigatto haemonetics.com Haemonetics Reports 2nd Quarter
Read more →HAEEarnings Release FY20 Q1 Investor Contacts Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Olg
Exhibit 99.1 Earnings Release FY20 Q1 Investor Contacts Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Olga Vlasova, Sr. Mgr.-Investor Relatio
Read more →HAEInvestor Contacts Media Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Carla Burigatto, VP-Communications (781) 348-7263 carla.burigatto@haemonetics.com Olga Vlasova, S
News Release Investor Contacts Media Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Carla Burigatto, VP-Communications (781) 348-7263 carla.burigatto@haemonetics.com Olga Vlasova, Sr. Mgr.-Investor Relations (781) 356-9763 olga.vlasova@h
Read more →HAEEarnings Release FY19 Q4 Investor Contacts Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Olg
Exhibit 99.1 Earnings Release FY19 Q4 Investor Contacts Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Olga Vlasova, Sr. Mgr.-Investor Relatio
Read more →HAEInvestor Contact: Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Media Contact: Carla Burigatto, VP-Communications (781) 348-7263 carla.burigatto@haemonetics.com Olga
Investor Contact: Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Media Contact: Carla Burigatto, VP-Communications (781) 348-7263 carla.burigatto@haemonetics.com Olga Vlasova, Sr. Mgr.-Investor Relations (781) 356-9763 olga.vlasova@haemonetics.com
Read more →HAEEarnings Release FY19 Q3 Investor Contacts Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Olg
Exhibit 99.1 Earnings Release FY19 Q3 Investor Contacts Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Olga Vlasova, Sr. Mgr.-Investor Relatio
Read more →HAEEarnings Release FY19 Q2 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Haem
Exhibit 99.1 Earnings Release FY19 Q2 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Haemonetics Reports 2nd Quarter and 1st H
Read more →HAEEarnings Release FY19 Q1 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Haem
Exhibit 99.1 Earnings Release FY19 Q1 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Haemonetics Reports 1st Quarter Fiscal 20
Read more →HAEEarnings Release FY18 Q4 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Haem
Exhibit 99.1 Earnings Release FY18 Q4 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Haemonetics Reports 4th Quarter and Fisca
Read more →HAEEarnings Release FY18 Q3 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Corr
Exhibit 99.1 Earnings Release FY18 Q3 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com This press release corrects a prior versi
Read more →HAEEarnings Release FY18 Q2 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Haem
Exhibit 99.1 Earnings Release FY18 Q2 Investor Contact Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com Haemonetics Reports 2nd Quarter Results a
Read more →HAEEarnings Release FY18 Q1 Investor Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Haemonetics Reports 1 st Quarter Fiscal 2018 Results Braintree, MA
Exhibit 99.1 Earnings Release FY18 Q1 Investor Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Haemonetics Reports 1st Quarter Fiscal 2018 Results Braintree, MA, August 7, 2017 - Haemonetics Corporation (NYSE: HAE) reported fin
Read more →HAEEarnings Release FY17 Q4 Investor Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Haemonetics Reports 4 th Quarter and Fiscal Year 2017 Results and Provides Fiscal 2018 Guidance Brai
Exhibit 99.1 Earnings Release FY17 Q4 Investor Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Haemonetics Reports 4th Quarter and Fiscal Year 2017 Results and Provides Fiscal 2018 Guidance Braintree, MA, May 8, 2017 - Haemonet
Read more →HAEEarnings Release FY17 Q3 Investor Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Media Contact Sandra Jesse, Executive VP (781) 356-9253 sandra.jesse@haemonetics.com Haemonetics Rep
Exhibit 99.1 Earnings Release FY17 Q3 Investor Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Media Contact Sandra Jesse, Executive VP (781) 356-9253 sandra.jesse@haemonetics.com Haemonetics Reports 3rd Quarter and
Read more →HAEEarnings Release FY17 Q2 Investor Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Media Contact Sandra Jesse, Executive VP (781) 356-9253 sandra.jesse@haemonetics.com Haemonetics Rep
Exhibit 99.1 Earnings Release FY17 Q2 Investor Contact Gerry Gould, VP-Investor Relations (781) 356-9402 gerry.gould@haemonetics.com Media Contact Sandra Jesse, Executive VP (781) 356-9253 sandra.jesse@haemonetics.com Haemonetics Reports 2nd Quarter and
Read more →HAEFOR RELEASE: CONTACT: Date
Exhibit 99.1 News Release FOR RELEASE: CONTACT: Date August 1, 2016 Gerry Gould, VP-Investor Relations Time 8:00 am Eastern Tel. (781) 356-9402 gerry.gould@haemonetics.com Alt. (781) 356-9613 Haemonetics Reports 1st Quarter Fiscal 2017 Results and Affirms Full Yea
Read more →HAEFOR RELEASE: INVESTOR CONTACT: Date
FOR RELEASE: INVESTOR CONTACT: Date May 9, 2016 Gerry Gould, VP-Investor Relations Time 5:00 pm Eastern (781) 356-9402 gerry.gould@haemonetics.com MEDIA CONTACT: Sandra Jesse, Executive VP (781) 356-9253 sandra.jesse@haemonetics.com Haemonetics Provides Fiscal 2017
Read more →HAEHaemonetics Pre-Announces 2 nd Quarter Results, Revises Fiscal Year 2016 Guidance and Sets Date for 2 nd Quarter Earnings Release
Haemonetics Pre-Announces 2nd Quarter Results, Revises Fiscal Year 2016 Guidance and Sets Date for 2nd Quarter Earnings Release: November 4, 2015 Braintree, MA, October 5, 2015 - Haemonetics Corporation (NYSE:HAE) today pre-announced that, based on preliminary information, it ex
Read more →HAEARCTender News Release FOR RELEASE: CONTACT: Date
FOR RELEASE: CONTACT: Date March 24, 2014 Gerry Gould, VP-Investor Relations Time 8:00AM Eastern Time Tel. (781) 356-9402 gerry.gould@haemonetics.com Alt. (781) 356-9613 Haemonetics Provides Update on U.S. Whole Blood Supply Tender March 24, 2014, Braintree, MA, USA - Haemo
Read more →HAEFOR RELEASE : CONTACT: Date
FOR RELEASE : CONTACT: Date January 27, 2014 Gerry Gould, VP-Investor Relations Time 6:00 am Eastern Tel. (781) 356-9402 gerry.gould@haemonetics.com Alt. (781) 356-9613 Haemonetics Reports 3rd Quarter Fiscal 2014 Revenue of $242 Million and $0.61 Adjusted EPS;
Read more →HAEEX-1.99 2 ex99101122014hemexcelpress.htm EXHIBIT EX99101122014HemeXcelPressRelease FOR RELEASE : CONTACT: Date
FOR RELEASE: CONTACT: Date January 12, 2014 Gerry Gould, VP-Investor Relations Time 4:00PM Eastern Time Tel. (781) 356-9402 gerry.gould@haemonetics.com Haemonetics Announces Signing of Supply Agreement with HemeXcel at J.P. Morgan Health Care Conference January 12, 2014, Bra
Read more →HAEHaemonetics Corporation Financial Summary (Unaudited data in thousands, except per share data) Consolidated Statements of Income for the Fourth Quarter of FY13 and FY12 3/30/2013 3/31/2012 % Inc/(Dec) As Reported As Repo
Three Months Ended 3/30/2013 3/31/2012 Whole Blood Acquisition Cost of Goods Sold $ 532 $ - Integration 8,195 - Y-Connector 984 - Restructuring and Transformation 2,760 2,774 HS Core Claims (37 ) (1,097 ) Transaction Costs 45 4,450 Arryx Disposition 4,791 - Contingent Considerati
Read more →Competitive Position
How HAE ranks across every disease it competes inCompetitive Position is a premium feature
See how HAE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial